Skip to content
  • 99%+ HPLC PURITY
  • FREE SHIPPING OVER $250
  • SECURE PAYMENT
  • US WAREHOUSE & FULFILMENT
  • SAME-DAY DISPATCH
SERVIAM IPAMORELIN, 5 milligram vial, 99.90%

Lyophilised powder · 99%+ documented HPLC

Ships from USAView COA

Ipamorelin Peptide

Selective growth-hormone secretagogue and ghrelin-receptor agonist studied in GH-axis models.

$49.99per 5mg vial

Vial size
1
Purity 99%+RP-HPLC documented
Identity conformsLC-MS verified
  • Ships from the US
  • Discreet packaging
  • Free shipping over $250
5aa
Length. Described in the source paper as the first selective compound of its class.
Raun et al., 1998
3×
Hormones that did NOT rise meaningfully alongside growth hormone — cortisol, ACTH and prolactin. This is the selectivity the paper reports.
Raun et al., 1998
1998
Year it was first characterised, at Novo Nordisk.
Eur J Endocrinol 1998
GHRP
The receptor route it acts through, established by blocking that route and watching the effect disappear.
Eur J Endocrinol 1998

Figures are structural data from our specification and certificates, or are drawn from published third-party literature about the compound, and are provided for orientation only. Nothing here is a claim about what this material does. Supplied for laboratory research use only.

01About this compound

What Ipamorelin is

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue characterised by its selectivity. It is frequently cited as one of the more selective secretagogues in its class. It is supplied lyophilised with a consistently clean impurity profile by RP-HPLC.

Class
GH secretagogue
Residues
5 amino acids
Formula
C38H49N9O5
Molecular weight
711.85 g/mol
CAS
170851-70-4
Presentation
5mg and 10mg vials
Form
Lyophilised powder
Sequence
  1. Aib
  2. His
  3. D
  4. 2
  5. Nal
  6. D
  7. Phe
  8. Lys
  9. NH2
BACKBONE IMPRESSION · NOT A STRUCTURAL MODEL
Atomic composition
101atoms
  • 38
  • 49
  • 9
  • 5

C38H49N9O5 · composition, not conformation

02Mechanism

How Ipamorelin
has been studied.

Signalling pathways examined in preclinical models. Descriptive of published research directions, not claims of effect.

GHS-R1a

Ghrelin receptor binding

Characterised as an agonist at the growth hormone secretagogue receptor, studied in receptor-expressing cell preparations.

  • Assessed at GHS-R1a
  • Studied in receptor-expressing lines
  • Compared against other secretagogues
Endocrine

GH pulse models

Studied for pulsatile growth-hormone release patterns in rodent models, where the shape of the release curve rather than its size is the endpoint.

  • Pulsatile release patterns
  • Rodent secretory dynamics
Pharmacology

Selectivity profile

A substantial part of the published characterisation concerns what Ipamorelin does not do relative to earlier secretagogues, which is the basis of its reputation for selectivity.

  • Profiled against related receptor targets
  • Compared with GHRP-class analogs
  • Examined in secretory dynamics models
03Uses & applications

What Ipamorelin is researched for

Selectivity

Raun et al., Eur J Endocrinol 1998

Growth hormone rose without a meaningful rise in cortisol, ACTH or prolactin.

Route confirmed

Blocking experiments, 1998

Blocking experiments placed the effect at a specific receptor rather than a general one.

Comparison

Against the older class, 1998

Strength and maximum effect were comparable to the older compound it was measured against.

04Class comparison

How it compares in its class

Reference class characteristics for orientation. Half-life figures are typical literature values, not lot measurements.

CompoundReceptor classTypical half-lifeNote
IpamorelinGHS-R1a agonist (pentapeptide)~2 hoursSelective, no cortisol rise
TesamorelinGHRH analogueShortActs upstream at the GHRH receptor
GHRP-6GHS-R1a agonist (hexapeptide)ShortRaises cortisol and appetite
05Research history

Class research timeline

Milestones in the study of this compound class.

  1. 1998

    Characterised at Novo Nordisk and reported as the first selective growth hormone secretagogue of its class.

  2. 2000

    Compared against GHRP-2 on cortisol and GH secretion profiles.

  3. 2001

    Ghrelin and GHS receptor function characterised, clarifying the route it acts through.

  4. 2004

    Studied in human nocturnal sleep, where GH rose during early sleep phases without cortisol disruption.

06Documentation

Certificates of analysis

Every lot is documented by an independent laboratory. The newest lot appears first.

LotReportedSizeHPLCLaboratoryCertificate
VNA7TB12 May 202610mg99.90%Freedom DiagnosticsView
IPA10-02242026-J27 Feb 202610mg99.657%Freedom DiagnosticsView
50000120 Feb 202610mg99.984%Freedom DiagnosticsView
Newest lot

99.90%

HPLC purity

Lot
VNA7TB
Certificate reported
12 May 2026
Released to sale
15 May 2026
Size
10mg
Identity
Confirmed (LC-MS)
Content
13.12mg
Appearance
White lyophilised powder
Laboratory
Freedom Diagnostics
Accession
2605110191
Search code
Auth2605110191
Open newest certificate

The signed PDF is the full certificate. The accession and search code above resolve the same record at the laboratory.

07Third-party verified

Independently tested.
Verifiably pure.

  • HPLC purity

    RP-HPLC, 214 nm

    PASS
  • Identity

    LC-MS

    CONFIRMED
Certificate of analysis

Lot VNA7TB

PASS
RP-HPLC · 214nm12 May 2026
HPLC purity
99.90%
Identity
Confirmed (LC-MS)
Laboratory
Freedom Diagnostics
Net content
13.12mg
Open the signed certificate
08Full specification

Every field on the label

Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular formula
C38H49N9O5
Molecular weight
711.85 g/mol
CAS / identifier
170851-70-4
Quantity per vial
5 mg
Purity
99.90% by RP-HPLC, 214 nm
Identity
Confirmed (LC-MS)
Appearance
White lyophilised cake
Solubility
Soluble in bacteriostatic water
Storage
-20°C long term, protect from light
Ships from
United States
Lot
VNA7TB
Assay date
12 May 2026
09Common questions

About Ipamorelin

Still unsure? Ask the lab, median response under four hours.

This material is supplied as a reference standard for in-vitro laboratory research only. It has not been evaluated by the FDA, is not a drug, and is not intended for human or veterinary use. Handling should follow your institution's chemical hygiene plan, including appropriate PPE and documented disposal.

Every lot is documented at 99%+ by RP-HPLC with identity confirmed by LC-MS, run by an independent laboratory. Released lots have measured between 99.657% and 99.984%; the figure for the lot you receive is in the certificate table above.

Yes. Every lot ships with its own signed certificate, and all three are published in the COA library, including for lots no longer in stock.

5mg and 10mg vials. The certificates on file are all 10mg lots, because that is the fill size tested to date.

Aib-His-D-2-Nal-D-Phe-Lys-NH2 — five residues, three of them non-standard, which is why it is written as a modified sequence rather than a plain letter string. Note that the residue count is stated as 9 in some published summaries; 5 is what the formula C38H49N9O5 corresponds to, and what the source paper reports. Identity is confirmed lot-by-lot against a certified reference standard by LC-MS.

Published characterisation focuses on its behaviour at the growth hormone secretagogue receptor relative to its activity at related targets. In the 1998 paper, growth hormone rose without a meaningful rise in cortisol, ACTH or prolactin — the three the older compounds in its class did raise. Researchers commonly select it for that comparatively narrow profile.

Store the sealed vial at −20°C for long-term stability and 2–8°C for short-term handling. Protect from light and avoid repeated freeze-thaw cycles. Compound-specific stability data is printed on the certificate of analysis supplied with the lot.

10Cited sources

Published literature

Independent published research relating to this compound. Listed for reference; Serviam Bio Labs is not affiliated with these authors and makes no claims based on their findings.

  1. [1]

    Ipamorelin, the first selective growth hormone secretagogue

    Raun K et al. · 1998 · European Journal of Endocrinology

  2. [2]

    Pharmacokinetic-pharmacodynamic modeling of ipamorelin

    Gobburu JV et al. · 1999 · Pharmaceutical Research

Search Ipamorelin on PubMed
Research encyclopedia

The Ipamorelin monograph

The full reference entry: molecular data, the mechanisms described in the literature, what the research covers, the specification and the papers behind it.

Read the monograph

For laboratory research use only. All compounds listed on this site are sold strictly as reference materials for in-vitro laboratory research conducted by qualified professionals. They are not drugs, foods, cosmetics, or medical devices. They are not intended for human or veterinary consumption, therapeutic use, diagnostic application, or any in-vivo use whatsoever. These statements have not been evaluated by the Food and Drug Administration. By purchasing, you affirm that you are a qualified researcher and that you will comply with all applicable institutional, local, state and federal regulations governing the handling of research chemicals.